{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T03:55:30Z","timestamp":1775015730694,"version":"3.50.1"},"reference-count":27,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bill and Melinda Gates Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Rubella infection is typically mild or asymptomatic except when infection occurs during pregnancy. Infection in early pregnancy can cause miscarriage, stillbirth, or congenital rubella syndrome. Only individuals that are still susceptible to rubella infection during child-bearing age are vulnerable to this burden. Rubella-containing vaccine (RCV) is safe and effective, providing life-long immunity. However, average age-at-infection increases with increasing vaccination coverage, which could potentially lead to increased disease burden if the absolute risk of infection during child-bearing age increases. The dynamics of rubella transmission were explored using EMOD, a software tool for building stochastic, agent-based infection models. Simulations of pre-vaccine, endemic transmission of rubella virus introduced RCV at varying levels of coverage to determine the expected future trajectories of disease burden. Introducing RCV reduces both rubella virus transmission and disease burden for a period of around 15 years. Increased disease burden is only possible more than a decade post-introduction, and only for contexts with persistently high transmission intensity. Low or declining rubella virus transmission intensity is associated with both greater burden without vaccination and greater burden reduction with vaccination. The risk of resurgent burden due to incomplete vaccination only exists for locations with persistently high infectivity, high connectivity, and high fertility. A trade-off between the risk of a small, future burden increase versus a large, immediate burden decrease strongly favors RCV introduction.<\/jats:p>","DOI":"10.3390\/vaccines12070811","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T11:40:36Z","timestamp":1721734836000},"page":"811","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Congenital Rubella Syndrome Does Not Increase with Introduction of Rubella-Containing Vaccine"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3383-2730","authenticated-orcid":false,"given":"Kurt","family":"Frey","sequence":"first","affiliation":[{"name":"Institute for Disease Modeling, Bill and Melinda Gates Foundation, Seattle, WA 98109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/S0140-6736(14)60539-0","article-title":"Rubella","volume":"385","author":"Lambert","year":"2015","journal-title":"Lancet"},{"key":"ref_2","unstructured":"Centers for Disease Control and Prevention (2021). Epidemiology and Prevention of Vaccine-Preventable Diseases."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7196\/sajch.461","article-title":"Congenital rubella\u2014Is it nearly time to take action?","volume":"6","author":"Boshoff","year":"2012","journal-title":"S. Afr. J. Child Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1016\/j.vaccine.2019.08.050","article-title":"Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis","volume":"37","author":"Zimmermann","year":"2019","journal-title":"Vaccine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijid.2023.09.003","article-title":"Estimates of the global burden of Congenital Rubella Syndrome, 1996\u20132019","volume":"137","author":"Vynnycky","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0149160","article-title":"Using Seroprevalence and Immunisation Coverage Data to Estimate the Global Burden of Congenital Rubella Syndrome, 1996\u20132010: A Systematic Review","volume":"11","author":"Vynnycky","year":"2016","journal-title":"PLoS ONE"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e011526","DOI":"10.1136\/bmjgh-2022-011526","article-title":"Cost-effectiveness of measles and rubella elimination in low-income and middle-income countries","volume":"8","author":"Levin","year":"2023","journal-title":"BMJ Glob. Health"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/ije\/9.1.13","article-title":"Strategy for Rubella Vaccination","volume":"9","author":"Knox","year":"1980","journal-title":"Int. J. Epidemiol."},{"key":"ref_9","unstructured":"ESRI (2023, December 31). World Countries\u2014Generalized, Available online: https:\/\/hub.arcgis.com\/datasets\/esri::world-countries-generalized\/explore."},{"key":"ref_10","unstructured":"World Health Organization (2020). Rubella vaccines: WHO position paper\u2014July 2020. Wkly. Epidemiol. Rec., 95, 306\u2013324."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1017\/S0950268899003532","article-title":"Sero-epidemiology of rubella in the urban population of Addis Ababa, Ethiopia","volume":"124","author":"Cutts","year":"2000","journal-title":"Epidemiol. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20130643","DOI":"10.1098\/rsif.2013.0643","article-title":"Characterizing the dynamics of rubella relative to measles: The role of stochasticity","volume":"10","author":"Rozhnova","year":"2013","journal-title":"J. R. Soc. Interface"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60712-1","article-title":"Rubella outbreak in Japan","volume":"383","author":"Ujiie","year":"2014","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.vaccine.2020.11.050","article-title":"Challenges in measuring supplemental immunization activity coverage among measles zero-dose children","volume":"39","author":"Cutts","year":"2021","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"fty059","DOI":"10.1093\/femspd\/fty059","article-title":"Implementation and applications of EMOD, an individual-based multi-disease modeling platform","volume":"76","author":"Bershteyn","year":"2018","journal-title":"Pathog. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100127","DOI":"10.1016\/j.jvacx.2021.100127","article-title":"Examination of scenarios introducing rubella vaccine in the Democratic Republic of the Congo","volume":"9","author":"Cheng","year":"2021","journal-title":"Vaccine X"},{"key":"ref_17","unstructured":"United Nations Department of Economic and Social Affairs, Population Division (2022). World Population Prospects 2022: Summary of Results, United Nations Department of Economic and Social Affairs, Population Division."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(82)92677-0","article-title":"Consequences of Confirmed Maternal Rubella at Successive Stages of Pregnancy","volume":"320","author":"Miller","year":"1982","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/risa.12264","article-title":"Characterization of the Risks of Adverse Outcomes Following Rubella Infection in Pregnancy","volume":"36","author":"Thompson","year":"2016","journal-title":"Risk Anal."},{"key":"ref_20","first-page":"1","article-title":"Evaluating the potential impact of rubella-containing vaccine introduction on congenital rubella syndrome in Afghanistan, Dem. Republic of Congo, Ethiopia, Nigeria, and Pakistan: A mathematical modeling study","volume":"4","author":"Zhang","year":"2024","journal-title":"PLoS Glob. Public Health"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Nakase, T., Brownwright, T., Okunromade, O., Egwuenu, A., Ogunbode, O., Lawal, B., Akanbi, K., Grant, G., Bassey, O.O., and Coughlin, M.M. The impact of sub-national heterogeneities in demography and epidemiology on the introduction of rubella vaccination programs in Nigeria. Vaccine, 2024. in press.","DOI":"10.1016\/j.vaccine.2024.05.030"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1126\/science.aau6299","article-title":"Measles and the canonical path to elimination","volume":"364","author":"Graham","year":"2019","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1017\/S0950268800004672","article-title":"The pre-vaccination epidemiology of measles, mumps and rubella in Europe: Implications for modelling studies","volume":"125","author":"Edmunds","year":"2000","journal-title":"Epidemiol. Infect."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1136\/bmj.319.7223.1462","article-title":"Increase in congenital rubella occurrence after immunisation in Greece: Retrospective survey and systematic review. How does herd immunity work?","volume":"319","author":"Panagiotopoulos","year":"1999","journal-title":"BMJ"},{"key":"ref_25","unstructured":"US Center for Disease Control (2021). Nationwide Campaign for Vaccination of Adults Against Rubella and Measles\u2014Costa Rica, 2001. Morb. Mortal. Wkly. Rep., 50, 976\u2013979."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pcbi.1008858","article-title":"Estimates of the basic reproduction number for rubella using seroprevalence data and indicator-based approaches","volume":"18","author":"Papadopoulos","year":"2022","journal-title":"PLoS Comput. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lessler, J., and Metcalf, C.J.E. (2013). Balancing Evidence and Uncertainty when Considering Rubella Vaccine Introduction. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0067639"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/7\/811\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:20:53Z","timestamp":1760109653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/7\/811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["vaccines12070811"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12070811","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]}}}